Eli Lilly and Company has announced new Phase 1 clinical trial data for its investigational folate receptor alpha (FRα) targeting antibody-drug conjugate $(ADC)$, LY4170156, at the 2025 ASCO Annual Meeting. The trial focused on women with heavily pre-treated platinum-resistant ovarian cancer, including those previously treated with mirvetuximab soravtansine. The findings revealed an encouraging safety profile and anti-tumor activity across varying doses and FRα expression levels, with a preliminary overall objective response rate of 55% at a potential recommended Phase 2 dose of 4 mg/kg. The ADC comprises an Fc-silent, FRα specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor. These results suggest potential for expanding treatment options for ovarian cancer patients and will be further investigated in registrational Phase 3 clinical trials.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.